Parathyroid hormone (1-34) (human) in CKD VC

Parathyroid hormone (1-34) (human) is a 34-amino-acid biologically active fragment that preserves the receptor-facing region of native human PTH. For researchers, its value is not limited to a single endpoint: the peptide can serve as a controlled stimulus for proximal receptor pharmacology, calcium homeostasis studies, bone metabolism research, and disease-relevant models of chronic kidney disease (CKD) and valvular calcification (VC). APExBIO supplies this research-use-only material as SKU A1129.

The most productive way to use the compound is to treat it as an experimental perturbation rather than as a standalone disease model. Begin with a receptor-proximal response, establish a concentration window, and then connect that response to endothelial-to-mesenchymal transition (EndMT), valve interstitial cell behavior, osteogenic markers, or tissue-level calcification. The workflow below is designed to make those connections measurable and interpretable.

Setup and principle overview

The peptide sequence is H2N-SVSEIQLMHNLGKHLNSMERVEWLRKKLQDVHNF-OH, with a reported molecular weight of 4117.72 Da. It engages parathyroid hormone 1 receptor and parathyroid hormone 2 receptor signaling, with downstream effects that include cAMP generation, calcium mobilization, renal calcium and magnesium handling, and indirect stimulation of intestinal calcium absorption through activated vitamin D production. These properties make it a practical parathyroid hormone receptor agonist for mechanistic experiments, while the short fragment format supports defined dosing and straightforward dilution.

According to the Parathyroid hormone (1-34) (human) product information, receptor binding has an IC50 of 2 nM and cAMP production in receptor-expressing human kidney 293 cells has an IC50 of 0.22 nM. Inositol phosphate synthesis is stimulated at concentrations of at least 24 nM. These values suggest a useful assay hierarchy: cAMP is a sensitive early readout, receptor binding confirms target engagement, and inositol phosphate measurements may require a higher exposure range or a more responsive cellular background.

That hierarchy matters in CKD and valve studies. A weak phenotype may reflect inadequate receptor activation, while a strong phenotype at a high concentration may include pathway saturation or nonphysiological stress. Pairing a low-nanomolar signaling assay with a 24- to 48-hour phenotypic assay helps distinguish direct PTH receptor activity from secondary changes in cell state.

Step-by-step workflow and protocol enhancements

Step 1: Define the biological question

For acute pharmacology, measure cAMP or receptor binding before examining gene expression. For bone metabolism research or an osteoporosis model, prioritize osteoblast or osteoclast-associated functional endpoints, matrix deposition, and mineralization. For CKD-related VC, use valve endothelial cells (VECs), valve interstitial cells (VICs), or a VEC–VIC co-culture and measure both endothelial preservation and osteogenic conversion.

The reference study is especially useful for selecting paired endpoints. Its central model links PTH-associated EndMT in valve endothelium to downstream VIC osteogenic behavior. Therefore, a calcification assay alone is insufficient: include endothelial markers such as VE-cadherin or ZO-1, mesenchymal markers, pathway measurements involving Jagged-1 and Notch, and a mineralization readout.

Step 2: Prepare a controlled peptide exposure

The material is supplied as a solid and is reported to be soluble at at least 19.88 mg/mL in water and at least 399.3 mg/mL in DMSO, but insoluble in ethanol. Use water when the downstream assay is sensitive to organic solvent, and include a matched vehicle control whenever DMSO is selected. Because the supplier recommends prompt use of prepared solutions, avoid treating a reconstituted stock as a long-term reagent. Store the dry material desiccated at -20 °C and minimize repeated freeze–thaw cycles.

Step 3: Establish proximal signaling before phenotyping

Run a concentration-response series that brackets the reported cAMP and receptor-binding values. A logarithmic design is more informative than testing only one nominal concentration. Record both the maximal response and the concentration producing half-maximal activity, then carry forward a submaximal concentration and a near-maximal concentration into longer assays. This approach can reveal whether Foxp1 or Notch manipulation changes PTH sensitivity, maximal signaling, or only the later transcriptional response.

Step 4: Build the EndMT and calcification workflow

Expose VECs to PTH (1-34) peptide fragment under conditions that preserve a healthy untreated control. At early time points, quantify cAMP and pathway activation. At later time points, assess endothelial junctional proteins, cell morphology, migration, mesenchymal transition, and secreted factors. In a co-culture or conditioned-medium design, expose VICs to the endothelial output and measure osteogenic transition separately. This division helps determine whether the peptide acts directly on VICs, indirectly through VEC-derived signals, or through both compartments.

Protocol Parameters

• Stock preparation: Prepare a 1 mg/mL working stock in sterile water at 20–25 °C, mix for 10 seconds, and use within 2 hours; if DMSO is required, include a vehicle-matched control at the final solvent concentration.
• Proximal signaling series: Test 0.01, 0.1, 0.22, 1, 2, 10, 24, and 100 nM for 15–30 minutes at 37 °C before collecting cAMP or receptor-proximal samples.
• EndMT pilot: Compare 0.22 nM and 2 nM peptide exposures for 24 and 48 hours at 37 °C with untreated and vehicle controls; designate these as exploratory starting conditions rather than universal optima.
• VEC–VIC comparison: Seed each cell population at approximately 1 × 10⁴ cells/cm², expose endothelial cultures for 24 hours, and transfer conditioned medium to VICs for 24–48 hours before measuring osteogenic or matrix endpoints.
• In vivo bone benchmark: For an ethically approved rat study, use the reported subcutaneous comparison of 10 or 40 µg/kg/day for 1–4 weeks and quantify trabecular and cortical bone outcomes at matched time points; do not extrapolate these research doses to clinical use.

Key Innovation from the Reference Study

The reference study advances the CKD valvular calcification field by placing endothelial Foxp1 upstream of a specific signaling sequence rather than viewing calcification as an isolated VIC defect. Using endothelial-specific Foxp1 overexpression in a CKD model, the investigators observed reduced valvular calcification and suppressed EndMT. Mechanistically, Foxp1 bound the Jagged-1 promoter and repressed its transcription, thereby dampening Notch pathway activation. The study further connected this change with lower TGF-β1 secretion, less osteogenic transition in VICs, restoration of endothelial integrity, and reduced HMGB1-driven macrophage infiltration.

This finding translates directly into assay design. Instead of asking only whether PTH increases mineral deposition, use a staged panel: first quantify PTH-triggered cAMP, then measure Jagged-1 and Notch activation in VECs, next assess EndMT markers and TGF-β1 output, and finally test VIC osteogenic conversion. A Foxp1 gain-of-function or loss-of-function comparison can show whether the response is pathway-sensitive. Chromatin immunoprecipitation followed by quantitative PCR at the Jagged-1 promoter is an especially relevant mechanistic validation when the goal is to reproduce the study’s regulatory logic.

Advanced applications and comparative advantages

Bone and osteoporosis-oriented studies

Intermittent PTH signaling is widely used as a research tool for studying bone formation and remodeling. In male Fisher 344 rats, the product dossier reports dose- and time-dependent increases in trabecular and cortical bone mass after subcutaneous administration of 10 or 40 µg/kg/day for up to 4 weeks. Link those exposure groups to microcomputed tomography, histomorphometry, and serum calcium measurements, while keeping sampling time consistent. This makes the fragment useful as a positive biological stimulus in an osteoporosis model, not merely as a receptor-ligand control.

For a broader mechanistic framework, the existing Atomic Mechanisms article complements this workflow by emphasizing receptor engagement and cAMP pathway interpretation. It is most useful when planning proximal signaling experiments, whereas the present workflow extends those concepts into EndMT and tissue remodeling. The Precision in Bone and Calcium Homeostasis article provides a complementary bone-focused perspective; use it to contrast acute calcium homeostasis assays with longer remodeling studies.

CKD and valvular calcification models

In a CKD valve model, the PTH (1-34) peptide fragment can function as a reproducible upstream challenge for testing whether endothelial protection changes downstream calcification. A useful comparison includes untreated VECs, PTH-exposed VECs, Foxp1-modulated VECs, and a combined Foxp1-plus-PTH condition. Add a VEC-free VIC arm to determine whether endothelial signaling is required for the observed phenotype. This design separates PTH/PTHrP receptor signaling from the secondary inflammatory and matrix changes that emerge in a multicellular system.

The comparative advantage of the fragment is experimental control. Its defined sequence, reported molecular weight, and quantified receptor and cAMP activity allow investigators to describe exposure more precisely than an undefined endocrine mixture. However, it should not automatically be treated as identical to every endogenous PTH pattern. Pulse duration, receptor expression, serum composition, calcium concentration, and cell differentiation state can all change the response.

Why this cross-domain matters, maturity, and limitations

Bone remodeling, serum calcium regulation, and CKD-related VC share PTH biology but are not interchangeable experimental domains. The product dossier supports bone and receptor studies, while the reference study supports a mechanistic relationship between PTH-associated EndMT and CKD valvular calcification. Together, they justify using this peptide to test pathway hypotheses across models, but they do not prove that the commercial fragment prevents or reverses human valve disease. Results should therefore be reported as model-specific pharmacology, with animal ethics, dose justification, and appropriate calcium controls.

Troubleshooting and optimization tips

No detectable cAMP response

Confirm receptor expression and assay dynamic range with a validated positive control before concluding that the peptide is inactive. Check peptide dilution calculations, avoid ethanol, and verify that the final concentration actually spans the reported 0.22 nM cAMP activity point. If the response remains weak, extend the range upward while preserving vehicle matching, then compare cell passage number and confluence.

High basal signaling or a compressed dose curve

High basal cAMP can mask an agonist response. Reduce serum-related variability, shorten the preincubation, and collect acute samples at a consistent time. A compressed curve may indicate receptor saturation, excessive peptide carryover, or insufficient concentration spacing. Include technical replicates and fit the full curve rather than relying on a single midpoint.

Peptide loss, precipitation, or inconsistent replicates

Use low-binding tubes, make small single-use aliquots, and document the time between dilution and addition to cells. Do not use ethanol as a solvent. If DMSO is used, keep the vehicle identical across wells and verify that the final solvent concentration does not alter cell morphology. Reconstitute a fresh aliquot when a stored solution gives a delayed or variable response.

EndMT signal without calcification

EndMT and mineral deposition have different kinetics. Confirm early loss of endothelial markers and later VIC responses independently. If only morphology changes, measure VE-cadherin, ZO-1, mesenchymal markers, Jagged-1, Notch activation, and TGF-β1 before assigning a calcific mechanism. A cell-density mismatch or an overly short culture window can also produce apparent EndMT without a robust mineral endpoint.

Future outlook

The most informative next step is a layered PTH challenge that integrates receptor-proximal cAMP, endothelial state, Jagged-1/Notch activity, TGF-β1 output, VIC osteogenic transition, and tissue calcification. This design can clarify where Foxp1-mediated protection acts and whether endothelial integrity is sufficient to reduce downstream remodeling signals. It also creates a common quantitative framework for comparing bone, kidney, and valve models without assuming that one endpoint represents the entire biology.

Future studies should preserve the distinction between pathway validation and therapeutic inference. The current evidence supports Foxp1 regulation of Jagged-1/Notch-associated EndMT in CKD-related VC and supports the peptide’s use in receptor, calcium, and bone research. It does not establish a clinical treatment protocol. Used with matched controls, short handling times, and orthogonal readouts, Parathyroid hormone (1-34) (human) can provide a precise research stimulus for testing how PTH signaling intersects with endothelial preservation and calcific remodeling. The material is intended for scientific research only and not for diagnostic or medical use.